ProCE Banner Activity

CME

Unfolding Immunotherapy in Head and Neck Cancer

Video

Watch this on-demand webcast from an August 2023 webinar featuring Barbara Burtness, MD, and Ranee Mehra, MD, discussing the latest clinical guidance and expert recommendations on incorporating immunotherapy in head and neck cancers.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: September 12, 2023

Expiration: September 11, 2024

Share

Faculty

Barbara Burtness

Barbara Burtness, MD

Anthony N. Brady Professor of Medicine
Yale School of Medicine
Chief Translational Research Officer
Division Chief
Head and Neck/Sarcoma Oncology
Co-leader
Developmental Therapeutics Program
Director
Yale Head and Neck SPORE
Yale Cancer Center
Chair
ECOG-ACRIN Cancer Research Group
New Haven, Connecticut

Ranee Mehra

Ranee Mehra, MD

Professor of Medicine
Department of Hematology/Oncology
University of Maryland, Baltimore
Director
Head and Neck Medical Oncology
Marlene and Stewart Greenebaum Comprehensive Cancer Center
University of Maryland Medical Center
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme, LLC

Target Audience

This educational program is intended for medical, surgical, and radiation oncologists and other healthcare professionals who treat patients with head and neck cancer.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners to apply immunotherapy in the treatment of patients with head and neck cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Analyze the role of the immune system and immune escape in HNSCC, and distinguish the mechanisms of action of different immunomodulatory agents

  • Synthesize the application of immune checkpoint inhibitors in the clinical management of patients with recurrent or metastatic HNSCC in both the frontline and relapsed/refractory settings through the integration of evidence-based practice

  • Evaluate, classify, and manage the unique spectrum of adverse events related to immune checkpoint inhibitors using critical-thinking skills and knowledge of best practices

  • Evaluate the latest scientific and clinical trial outcomes concerning immune checkpoint inhibitors alone or in combination with radiotherapy or biotherapy in adjuvant and neoadjuvant settings using an evidence-based approach

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Barbara Burtness, MD

Anthony N. Brady Professor of Medicine
Yale School of Medicine
Chief Translational Research Officer
Division Chief
Head and Neck/Sarcoma Oncology
Co-leader
Developmental Therapeutics Program
Director
Yale Head and Neck SPORE
Yale Cancer Center
Chair
ECOG-ACRIN Cancer Research Group
New Haven, Connecticut

Barbara Burtness, MD: consultant/advisor/speaker: ALX Oncology, Coherus, CUE Biopharma, Eisai, GlaxoSmithKline, Kura, Merck, Merck KgA, Merus, Orphagen; researcher: CUE Biopharma, Merck, Merck KgA.

Ranee Mehra, MD

Professor of Medicine
Department of Hematology/Oncology
University of Maryland, Baltimore
Director
Head and Neck Medical Oncology
Marlene and Stewart Greenebaum Comprehensive Cancer Center
University of Maryland Medical Center
Baltimore, Maryland

Ranee Mehra, MD: consultant/advisor/speaker: Coherus, Janssen; researcher: AstraZeneca, Merck.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from September 12, 2023, through September 11, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

A logo for a companyDescription automatically generated with low confidence

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.